Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tepotinib Improves Prognosis in an Elderly Patient with Poor Performance Status and MET Exon 14 Skipping Mutation-positive Non-small Cell Lung Cancer.

The Tokai journal of experimental and clinical medicine - 20 Apr 2022

Tanaka Arihito, Kashizaki Fumihiro, Sugimoto Shunsuke, Hattori Shigeaki, Yazaki Natsumi, Obayashi Syohei, Kitahara Asako, Asano Koichiro

Abstract excerpt

Several target therapies for driver gene mutations related with lung cancer growth are clinically effective in patients with advanced non-small cell lung cancer. Gefitinib and alectinib have been reported as being effective and safe even in those with poor performance status (PS), but little is known about efficacy and tolerability of other TKIs. An 84-year-old man was diagnosed with non-small cell lung cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Exons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Piperidines

Share to Prognosis

Share to Proto-Oncogene Proteins c-met

Share to Pyridazines

Share to Pyrimidines

Source

Identifiers

PMID: 35383870

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tepotinib Improves Prognosis in an Elderly Patient with Poor Performance Status and MET Exon 14 Skipping Mutation-positive Non-small Cell Lung Cancer.PMID 35383870Read ↗

Tepotinib in patients with MET exon 14 skipping non-small cell lung cancerSemantic proximity Read ↗

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.Semantic proximity Read ↗

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?Semantic proximity Read ↗

Efficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping MutationSemantic proximity Read ↗

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future ChallengesSemantic proximity Read ↗

Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.Semantic proximity Read ↗

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.Semantic proximity Read ↗

Efficacy and tolerability of capmatinib in a very elderly patient with metastatic NSCLC harboring a MET exon 14 mutation.Semantic proximity Read ↗

Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.Semantic proximity Read ↗

Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.